NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $20.54 +3.29 (+19.07%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$20.33 -0.21 (-1.02%) As of 05/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Fulgent Genetics Stock (NASDAQ:FLGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fulgent Genetics alerts:Sign Up Key Stats Today's Range$17.92▼$20.9450-Day Range$15.28▼$20.5452-Week Range$14.57▼$25.11Volume851,635 shsAverage Volume266,523 shsMarket Capitalization$633.99 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingHold Company OverviewFulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More… Fulgent Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreFLGT MarketRank™: Fulgent Genetics scored higher than 55% of companies evaluated by MarketBeat, and ranked 413th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fulgent Genetics are expected to decrease in the coming year, from ($0.85) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.85% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 15.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.67 Percentage of Shares Shorted8.85% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 15.79%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.27 News SentimentFulgent Genetics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,596,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Stock News HeadlinesFulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathologyMay 2 at 9:44 PM | msn.comFulgent Genetics rises on earnings, revenue beatMay 2 at 4:43 PM | msn.comWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.May 3, 2025 | Stansberry Research (Ad)Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call TranscriptMay 2 at 1:09 PM | seekingalpha.comFulgent Reports First Quarter 2025 Financial ResultsMay 2 at 7:00 AM | businesswire.comFulgent Genetics (FLGT) Projected to Post Quarterly Earnings on FridayMay 1 at 1:45 AM | americanbankingnews.comFulgent Genetics Inc (FLGT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...April 21, 2025 | finance.yahoo.comFulgent Genetics (NASDAQ:FLGT) shareholders have endured a 69% loss from investing in the stock three years agoApril 11, 2025 | finance.yahoo.comSee More Headlines FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $18.47 at the beginning of the year. Since then, FLGT shares have increased by 11.2% and is now trading at $20.54. View the best growth stocks for 2025 here. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings data on Friday, May, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.12. The business's quarterly revenue was up 14.0% on a year-over-year basis. Read the conference call transcript. Does Fulgent Genetics have any subsidiaries? Fulgent Genetics subsidiaries include these companies: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' top institutional shareholders include Peapod Lane Capital LLC (0.53%), Bank of New York Mellon Corp (0.27%), GAMMA Investing LLC (0.24%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Paul Kim and Jian Xie. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET). Company Calendar Last Earnings5/02/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,010Year Founded2011Price Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside-22.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-59.39% Pretax Margin-68.09% Return on Equity-1.81% Return on Assets-1.66% Debt Debt-to-Equity RatioN/A Current Ratio4.41 Quick Ratio4.41 Sales & Book Value Annual Sales$283.47 million Price / Sales2.24 Cash Flow$4.01 per share Price / Cash Flow5.12 Book Value$38.24 per share Price / Book0.54Miscellaneous Outstanding Shares30,866,000Free Float20,873,000Market Cap$633.99 million OptionableOptionable Beta1.36 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FLGT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.